Ordonez Claudia 4
4 · Keros Therapeutics, Inc. · Filed Apr 14, 2021
Insider Transaction Report
Form 4
Ordonez Claudia
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-04-12$60.01/sh−367$22,024→ 233 total - Sale
Common Stock
2021-04-12$61.23/sh−233$14,267→ 0 total - Exercise/Conversion
Common Stock
2021-04-12$0.48/sh+1,000$480→ 1,000 total - Sale
Common Stock
2021-04-12$59.09/sh−400$23,636→ 600 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-04-12−1,000→ 100,211 totalExercise: $0.48Exp: 2029-09-18→ Common Stock (1,000 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.58 to $59.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.79 to $60.44 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $61.40 inclusive.
- [F5]One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.